068760 — Celltrion Pharm Share Price
0.000.00%
Last trade - 00:00- KR₩2tn
- KR₩2tn
- KR₩478bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.32 | ||
| Price to Tang. Book | 5.9 | ||
| Price to Free Cashflow | 41.69 | ||
| Price to Sales | 4.42 | ||
| EV to EBITDA | 38.29 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 8.82% | ||
| Return on Equity | 5.68% | ||
| Operating Margin | 7.79% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 233,568.48 | 398,738.21 | 386,039.61 | 388,794.34 | 477,835.31 | n/a | n/a | 22.46% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +123.86 | +65.79 | -25.1 | -11.01 | -4.79 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Celltrion Pharm Inc is a Korea-based company engaged in the manufacture and sale of pharmaceuticals. The Company’s products include hepatotonics, analgesics, antipyretics, anti-inflammatory drugs, antihistamines, respiratory apparatus drugs, circularly system drugs, digestives and stomachic drugs, hormone disease drugs, antibiotics, nutrients, tonics, and other drugs. It also provides ethical drugs and over-the-counter (OTC) drugs. The Company distributes its products in domestic market and overseas markets such as Philippines, Kazakhstan, Cambodia and other Southeast Asia countries.
Directors
- Jeong Su Seo CEO (61)
- Myeong Geun Oh SVP (56)
- Yeong Ho Yoo VPR (55)
- Seung Jae Choi MDR (55)
- Jin Gyu Wang MDR (57)
- Yeong Seop Lee OTH (67)
- Jeong Jin Seo DRC (63)
- Jin Seok Seo DRC (37)
- Gyeong Yeop Kim NID (64)
- Haeng Ok Kim NID (69)
- Wang Don Lee NID (65)
- Tae Yeong Song NID (60)
- Sang Wu Yang NID (58)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 17th, 2000
- Public Since
- February 3rd, 2006
- No. of Shareholders
- 126,003
- No. of Employees
- 920
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 43,453,023.48
- Address
- 82, 2sandan-ro, Ochang-eup, Cheongwon-gu, CHEONGJU, 28117
- Web
- https://www.celltrionph.com/ko-kr/home/index
- Phone
- +82 437177000
- Auditors
- Shinwoo Accounting Corp.
Upcoming Events for 068760
Q2 2025 Celltrion Pharm Inc Earnings Release
Q3 2025 Celltrion Pharm Inc Earnings Release
Similar to 068760
AbClon
Korea Exchange - KOSDAQ
ADBiotech Co
Korea Exchange - KOSDAQ
AHN-GOOK PHARMACEUTICAL Co
Korea Exchange - KOSDAQ
Alteogen
Korea Exchange - KOSDAQ
Aminologics Co
Korea Exchange - KOSDAQ
FAQ
What is the Celltrion Pharm share price?
As of Today at 19:50 UTC, shares in Celltrion Pharm are trading at KR₩48,550. This share price information is delayed by 15 minutes.
How has the Celltrion Pharm share price performed this year?
Shares in Celltrion Pharm last closed at KR₩48,550 and the price had moved by -43.85% over the past 365 days. In terms of relative price strength the Celltrion Pharm share price has underperformed the FTSE Developed Asia Pacific Index by -43.21% over the past year.
What are the analyst and broker recommendations for Celltrion Pharm?
The overall consensus recommendation for Celltrion Pharm is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Celltrion Pharm dividend yield?
Celltrion Pharm does not currently pay a dividend.
Does Celltrion Pharm pay a dividend?
Celltrion Pharm does not currently pay a dividend.
When does Celltrion Pharm next pay dividends?
Celltrion Pharm does not currently pay a dividend.
How do I buy Celltrion Pharm shares?
To buy shares in Celltrion Pharm you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Celltrion Pharm?
As of the previous close price of KR₩48,550, shares in Celltrion Pharm had a market capitalisation of KR₩2tn.
Where are Celltrion Pharm shares listed?
Here are the trading details for Celltrion Pharm:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 068760
What kind of share is Celltrion Pharm?
Based on an overall assessment of its quality, value and momentum Celltrion Pharm is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Celltrion Pharm share price forecast for 2025?
The analyst consensus target price for shares in Celltrion Pharm is KR₩136,000. That is 180.12% above the last closing price of KR₩48,550.
Analysts covering Celltrion Pharm currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Celltrion Pharm share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Celltrion Pharm. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -12.4%.
As of the last closing price of KR₩48,550, shares in Celltrion Pharm were trading -20.9% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Celltrion Pharm PE Ratio?
The Celltrion Pharm PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩48,550.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Celltrion Pharm?
Celltrion Pharm's management team is headed by:
- Jeong Su Seo - CEO
- Myeong Geun Oh - SVP
- Yeong Ho Yoo - VPR
- Seung Jae Choi - MDR
- Jin Gyu Wang - MDR
- Yeong Seop Lee - OTH
- Jeong Jin Seo - DRC
- Jin Seok Seo - DRC
- Gyeong Yeop Kim - NID
- Haeng Ok Kim - NID
- Wang Don Lee - NID
- Tae Yeong Song - NID
- Sang Wu Yang - NID